{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:19:12Z","timestamp":1783502352698,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031277","name":"Department for Energy Security and Net Zero","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031277","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to provide a comprehensive analysis of the increasing demand for PET-CT imaging in England, driven by advancements in technology and updated clinical guidelines. By comparing the 2013 and 2022 guidelines issued by the Royal College of Radiologists, the analysis sought to quantify the gap between actual PET-CT provision and modeled requirements, benchmarked against international comparators, to inform strategic planning for equitable access to advanced imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A detailed modeling approach was developed, mapping guideline-based PET-CT scan requirements to disease incidence and stage for major oncological indications (prostate, lymphoma, neuroendocrine tumors, lung, breast, gynecological cancers) and key non-oncological conditions (dementia, cardiovascular disease). Actual scan volumes were extracted from the NHS Diagnostic Imaging Dataset and cross-referenced with provider data. Unmodeled indications were estimated using proportional scaling. Model outputs were validated against PET-CT utilization rates in Finland, adjusted for UK disease incidence. Future demand projections incorporated population growth, demographic shifts, and evolving disease prevalence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For 2021, modeled estimates indicated a substantial shortfall in PET-CT provision for several high-impact indications, notably prostate cancer, dementia, neuroendocrine tumors, and breast cancer, where actual scan volumes were 2-7 times lower than modeled need. Modeled demand for England (361\u00a0900 scans\/year) exceeded actual provision (239\u00a0367 scans\/year) by over 50%. Comparative analysis with Finland confirmed that England\u2019s PET-CT rates lagged for most indications except lung cancer. Projections suggest continued growth in demand, particularly for dementia and neuroendocrine tumors, with overall PET-CT needs expected to rise sharply by 2040.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>England\u2019s current PET-CT capacity falls significantly short of evidence-based requirements, especially for emerging indications in neurology and oncology. Without strategic investment and expansion, this gap will widen, risking delayed diagnosis and suboptimal care. Enhanced data collection and ongoing validation are critical for responsive service planning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Advances in knowledge<\/jats:title>\n                    <jats:p>This is the first study to comprehensively model PET-CT demand in England across multiple disease categories using updated clinical guidelines and international benchmarking. It provides a robust, data-driven framework for forecasting imaging needs, supporting national policy and equitable resource allocation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjro\/tzag006","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:17:51Z","timestamp":1772695071000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing current and future demand for PET-CT imaging in England: a comparative analysis of 2013 and 2022 Royal College of Radiologists Guidelines"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6503-3001","authenticated-orcid":false,"given":"Nadia A S","family":"Smith","sequence":"first","affiliation":[{"name":"T\u00dcV S\u00dcD UK Nuclear Technologies, , Warrington, WA3 6AE,","place":["United Kingdom"]},{"name":"Scientific Computing, Royal Surrey NHS Foundation Trust , Guildford GU2 7XX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Nutbrown","sequence":"additional","affiliation":[{"name":"T\u00dcV S\u00dcD UK Nuclear Technologies, , Warrington, WA3 6AE,","place":["United Kingdom"]},{"name":"Department of Physics, University of Surrey , Guildford GU2 7XH,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Eisner","sequence":"additional","affiliation":[{"name":"University of Cambridge, Addenbrooke\u2019s Hospital Department of Oncology, , Cambridge, CB2 0QQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Jena","sequence":"additional","affiliation":[{"name":"University of Cambridge, Addenbrooke\u2019s Hospital Department of Oncology, , Cambridge, CB2 0QQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2026070804571586300_tzag006-B1","author":"Facts & Factors","year":"2023"},{"key":"2026070804571586300_tzag006-B2","author":"NHS England"},{"key":"2026070804571586300_tzag006-B3","author":"United Nations Development Programme (UNDP)"},{"key":"2026070804571586300_tzag006-B4","volume-title":"Evidence-Based Indications for the Use of PET-CT in the UK","author":"The Royal College of Radiologists","year":"2013"},{"key":"2026070804571586300_tzag006-B5","volume-title":"Evidence-Based Indications for the Use of PET-CT in the United Kingdom","author":"The Royal College of Radiologists","year":"2022"},{"key":"2026070804571586300_tzag006-B6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1053\/j.semnuclmed.2021.10.005","article-title":"Advances in PET\/CT technology: an update","volume":"52","author":"Aide","year":"2022","journal-title":"Semin Nucl Med"},{"key":"2026070804571586300_tzag006-B7","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s00259-021-05390-4","article-title":"New PET technologies\u2013embracing progress and pushing the limits","volume":"48","author":"Aide","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070804571586300_tzag006-B8","doi-asserted-by":"publisher","first-page":"101212","DOI":"10.1016\/j.adro.2023.101212","article-title":"Positron emission tomography (PET)\/computed tomography (CT) imaging in radiation therapy treatment planning: a review of pet imaging tracers and methods to incorporate PET\/CT","volume":"8","author":"Trotter","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"2026070804571586300_tzag006-B9","doi-asserted-by":"publisher","author":"European Association of Nuclear Medicine","DOI":"10.52717\/PWZE5872"},{"key":"2026070804571586300_tzag006-B10","author":"National Institute for Health and Care Excellence"},{"key":"2026070804571586300_tzag006-B11","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzaa166","article-title":"A comparative analysis: international variation in PET-CT service provision in oncology\u2014an International Cancer Benchmarking Partnership study","volume":"33","author":"Lynch","year":"2021","journal-title":"Int J Quality Health Care"},{"key":"2026070804571586300_tzag006-B12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/JU.0000000000001369","article-title":"Detection rate of prostate specific membrane antigen tracers for positron emission tomography\/computerized tomography in prostate cancer biochemical recurrence: a systematic review and network meta-analysis","volume":"205","author":"Crocerossa","year":"2021","journal-title":"J Urol"},{"key":"2026070804571586300_tzag006-B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/bmb\/ldy032","article-title":"Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer","volume":"128","author":"Afaq","year":"2018","journal-title":"Br Med Bull"},{"key":"2026070804571586300_tzag006-B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.crad.2016.08.003","article-title":"Clinical impact and diagnostic accuracy of 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography\/computed tomography (PET\/CT) brain imaging in patients with cognitive impairment: a tertiary centre experience in the UK","volume":"72","author":"Motara","year":"2017","journal-title":"Clin Radiol"},{"key":"2026070804571586300_tzag006-B15","author":"NHS England","year":"2015"},{"key":"2026070804571586300_tzag006-B16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/MNM.0000000000001736","article-title":"Brain PET and SPECT imaging and quantification: a survey of the current status in the UK","volume":"44","author":"Michopoulou","year":"2023","journal-title":"Nucl Med Commun"},{"key":"2026070804571586300_tzag006-B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/13558196231211141","article-title":"Expected wait times for access to a disease-modifying Alzheimer\u2019s treatment in England: a modelling study","volume":"29","author":"Mattke","year":"2024","journal-title":"J Health Serv Res Policy"},{"key":"2026070804571586300_tzag006-B18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.14283\/jpad.2024.24","article-title":"Estimated investment need to increase England\u2019s capacity to diagnose eligibility for an Alzheimer\u2019s treatment to G7 average capacity levels","volume":"11","author":"Mattke","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"2026070804571586300_tzag006-B19","author":"NHS England","year":"2024"},{"key":"2026070804571586300_tzag006-B20","year":"2015"},{"key":"2026070804571586300_tzag006-B21","author":"National Disease Registration Service (NDRS)","year":"2024"},{"key":"2026070804571586300_tzag006-B22","author":"NHS Digital","year":"2021"},{"key":"2026070804571586300_tzag006-B23","author":"Meadows"},{"key":"2026070804571586300_tzag006-B24","author":"Kuurne","year":"2023"},{"key":"2026070804571586300_tzag006-B25"},{"key":"2026070804571586300_tzag006-B26","author":"Office for National Statistics."},{"key":"2026070804571586300_tzag006-B27","year":"2015"},{"key":"2026070804571586300_tzag006-B28","year":"2015"},{"key":"2026070804571586300_tzag006-B29","year":"2015"},{"key":"2026070804571586300_tzag006-B30","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: a retrospective, population-based study","volume":"23","author":"White","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2026070804571586300_tzag006-B31","year":"2015"},{"key":"2026070804571586300_tzag006-B32","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/annonc\/mdz169","article-title":"Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy","volume":"30","author":"Pastorino","year":"2019","journal-title":"Ann Oncol"},{"key":"2026070804571586300_tzag006-B33","year":"2015"},{"key":"2026070804571586300_tzag006-B34","volume-title":"Dementia Incidence Trend in England and Wales 2002-2019 and Projection for Dementia Burden to 2040: English Longitudinal Study of Ageing","author":"Chen","year":"2023"},{"key":"2026070804571586300_tzag006-B35","volume-title":"Advances in PET\/CT Imaging","author":"Iskra","year":"2021"}],"container-title":["BJR|Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjro\/advance-article-pdf\/doi\/10.1093\/bjro\/tzag006\/67234997\/tzag006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjro\/article-pdf\/8\/1\/tzag006\/67234997\/tzag006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjro\/article-pdf\/8\/1\/tzag006\/67234997\/tzag006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:57:24Z","timestamp":1783501044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjro\/article\/doi\/10.1093\/bjro\/tzag006\/8506509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjro\/tzag006","relation":{},"ISSN":["2513-9878"],"issn-type":[{"value":"2513-9878","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"tzag006"}}